ScripInsmed may be making a best-in-class case in pulmonary arterial hypertension (PAH) for its inhaled powder formulation of treprostinil, the active ingredient in United Therapeutics’ blockbuster Tyvaso.
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T
ScripSweden's Vicore Pharma can now boast Sanofi as a backer as it kicks off mid-stage trials of its idiopathic pulmonary fibrosis (IPF) candidate, buloxibutid. The French drugmaker has committed to s
Generics BulletinSandoz and its generic Remodulin (treprostinil) partner Liquidia have welcomed a US court opinion that concluded the firms suffered losses of more than $137m as a result of interference by originat